1. Introduction {#sec1-marinedrugs-13-07074}
===============

Marine natural products have attracted attention in recent years as a rich and promising source of drug candidates, especially in the field of anticancer drug discovery \[[@B1-marinedrugs-13-07074]\]. In the majority of cases, only small quantities of the compounds could be isolated from the extracts of marine organisms such as sponges and tunicates; therefore, sustainable supply is the major limitation for further evaluation of these compounds and drug development. One of the solutions to address this issue is chemical synthesis of the active compounds and their analogs. Structure-activity relationship studies and syntheses of the truncated natural products give us further opportunities to generate more promising drug leads with optimized activity, chemical stability, and accessibility \[[@B2-marinedrugs-13-07074],[@B3-marinedrugs-13-07074]\].

It is widely accepted that hypoxia aggravates tumorigenesis by promoting tumor growth, angiogenesis, and metastasis, or by inducing resistance to chemotherapy and irradiation \[[@B4-marinedrugs-13-07074]\]. Therefore, compounds exhibiting hypoxia-selective growth inhibitory activity could be novel and promising drug leads for anticancer drug development \[[@B5-marinedrugs-13-07074]\], and the adaptation factors of tumor cells to hypoxia environment, with particular regard to hypoxia inducible factor-1 (HIF-1), have been extensively investigated as drug targets for cancer chemotherapy.

In our continuing search for bioactive compounds from marine organisms, we isolated dictyoceratin-C (**1**) \[[@B6-marinedrugs-13-07074]\] from the Indonesian marine sponge *Dactylospongia elegans* as a hypoxia-selective growth inhibitor, and found that dictyoceratin-A (**2**) \[[@B7-marinedrugs-13-07074]\] exhibited a similar biological activity ([Figure 1](#marinedrugs-13-07074-f001){ref-type="fig"}). These two sesquiterpene phenols inhibited the proliferation of human prostate cancer DU145 cells selectively under hypoxic condition in a dose-dependent manner at concentrations ranging from 1.0 to 10 μM, by inhibiting the accumulation of HIF-1α under hypoxic condition \[[@B8-marinedrugs-13-07074]\].

![Chemical structures of (+)-dictyoceratin-C (**1**) and -A (**2**).](marinedrugs-13-07074-g001){#marinedrugs-13-07074-f001}

To obtain compounds in sufficient yields for further evaluation, we recently reported the enantioselective total synthesis of **1** and **2**, with confirmation of absolute stereochemistry \[[@B9-marinedrugs-13-07074]\]. Moreover, we found that unnatural enantiomers of **1** and **2** also showed similar hypoxia-selective growth inhibitory activity against DU145 cells. It implies that the pharmacophore of these compounds is the *para*-hydroxybenzoyl ester moiety of the side chain and the chiral decalin moiety might not play a crucial role \[[@B9-marinedrugs-13-07074]\]. However, more precise structure-activity relationship (SAR) information is needed to develop promising anticancer drug leads based on these compounds. In this study, we investigated the *in vivo* antitumor effect of compounds **1** and **2** and analyzed their SAR through design and synthesis of various analog compounds.

2. Results and Discussion {#sec2-marinedrugs-13-07074}
=========================

2.1. In Vivo Antitumor Activity of **1** and **2** {#sec2dot1-marinedrugs-13-07074}
--------------------------------------------------

Enantioselective total synthesis of **1** and **2** yielded hundreds of milligrams of these compounds \[[@B9-marinedrugs-13-07074]\]. In order to verify the potential of these compounds as promising drug leads for cancer treatment, we examined their *in vivo* antitumor activity in mice subcutaneously inoculated with sarcoma S180 cells.

The compounds were orally administered every other day for two weeks, and the effectiveness of the compounds was determined by weighing the surged tumor on the day after final administration. Both compounds at 10--50 mg/kg inhibited the growth of implanted tumors, with \~90% reduction of the tumor weight at 50 mg/kg relative to respective control ([Figure 2](#marinedrugs-13-07074-f002){ref-type="fig"}). Moreover, no significant acute toxicities, such as weight loss or diarrhea, were observed during the study period for both compounds. This result indicated that compounds **1** and **2** are potential anticancer drug leads.

![*In* *vivo* antitumor effect of dictyoceratin-C (**1**) and A (**2**). (**a**) Mean ± SD of tumor weight of each group. \* *p* \< 0.05; (**b**) Images of surged tumors after two weeks.](marinedrugs-13-07074-g002){#marinedrugs-13-07074-f002}

2.2. Design and Synthesis of Structure-Modified Analogs {#sec2dot2-marinedrugs-13-07074}
-------------------------------------------------------

SAR study of **1** or **2** was performed to identify the important moiety for their biological activities. In the initial SAR study of some natural sesquiterpene phenols/quinones isolated from sponge extracts, *para*-hydroxybenzoyl ester moiety was found to play a significant role in the hypoxia-selective growth inhibitory activity \[[@B8-marinedrugs-13-07074],[@B9-marinedrugs-13-07074]\]. In order to examine the SAR in detail, we synthesized analogs of **1** or **2** by focusing on certain particular functional groups, such as methyl ester or hydroxyl group of the aromatic ring and *exo*-olefin or C-8 methyl groups in the decalin part ([Figure 3](#marinedrugs-13-07074-f003){ref-type="fig"}).

![Modification of functional groups for structure-activity relationship (SAR).](marinedrugs-13-07074-g003){#marinedrugs-13-07074-f003}

### 2.2.1. Modification of Aromatic Ring {#sec2dot2dot1-marinedrugs-13-07074}

Involvement of the functionality of the aromatic ring was analyzed. To elucidate the functional group crucial for the bioactivity and to develop more potent compounds, modification of the ester group and hydroxyl group of **1** was executed ([Scheme 1](#marinedrugs-13-07074-f006){ref-type="scheme"}).

![Synthesis of aromatic ring-modified analogs. Reagents and conditions: (**a**) Ph~3~PCH~3~Br, KHMDS, THF, 94%; (**b**) SOCl~2~, octanol, 50 °C, 13%; (**c**) EDCI·HCl, HOBt, propargylamine, DMF, 58%; (**d**) MeI, K~2~CO~3~, DMF, quant.; (**e**) propargyl bromide, K~2~CO~3~, DMF, **8**: 35%, **9**: 13%; (**f**) *n*-nonyl bromide, K~2~CO~3~, DMF, **10**: 21%, **11**: 14%.](marinedrugs-13-07074-g006){#marinedrugs-13-07074-f006}

First, octyl ester analog **5** and propargyl amide analog **6** were synthesized from compound **3**, an intermediate in the total synthesis of **1** \[[@B9-marinedrugs-13-07074]\], through Wittig olefination and subsequent condensation with *n*-octanol or propargylamine, respectively. Further, the phenolic hydroxyl group of **1** was alkylated with MeI and K~2~CO~3~ to provide a methyl ether analog **7**.

Second, participation of the respective hydroxyl groups of **2** was examined. In this analysis, propargyl and nonyl ether were selected to determine the relationship between lipophilicity/steric bulkiness and bioactivity. Alkylation of the diol group of **2** via a general method (alkyl bromide and K~2~CO~3~ in DMF) yielded a mixture of two mono-alkylated compounds, together with di-alkylated compound as a major product; a selective mono-alkylation condition could not be achieved. Fortunately, each mono-alkylated compound could be separated by open column chromatography to yield 17-*O*-alkylated analogs (**8**,**10**) and 18-*O*-alkylated analogs (**9**,**11**), respectively.

### 2.2.2. Modification of Decalin Part {#sec2dot2dot2-marinedrugs-13-07074}

Next, modification of the decalin part was examined. Many reaction steps were needed to elaborate the decalin part in a chemo- and stereoselective manner, mainly for the construction of 8α-methyl group and relatively unstable *exo*-olefin at C-4. Therefore, synthetic study of the truncated natural compounds might be effective for obtaining analogs with improved accessibility or stability or both.

First, modifications of the *exo*-olefin at C-4 of **1** were attempted ([Scheme 2](#marinedrugs-13-07074-f007){ref-type="scheme"}). Hydrogenation of **1** yielded 3,4-dihydro analog (**12**) as a diastereomixture (1:1), which was separated by HPLC to provide **12a** (4*S*) and **12b** (4*R*). Stereochemistry of each compound was determined by NOE experiment. Isomerization of the *exo*-olefin of **1** was accomplished by treatment with RhCl~3~·H~2~O in refluxing ethanol \[[@B10-marinedrugs-13-07074]\] to yield compound **13** having an internal olefin.

![Synthesis of exo-methylene-modified analogs. Reagents and conditions: (**a**) H~2~, Pd-C, MeOH (**12a**: 51%, **12b**: 47%); (**b**) RhCl~3~·H~2~O, EtOH, reflux, 61%.](marinedrugs-13-07074-g007){#marinedrugs-13-07074-f007}

Next, transformation of the 8-methyl group of **1** was also examined ([Scheme 3](#marinedrugs-13-07074-f008){ref-type="scheme"}). We designed and synthesized 8-hydroxyl and 8-desmethyl analogs from 8-keto compound **14**, an intermediate in the total synthesis of **1**. Reduction of the ketone of **14** by NaBH~4~ yielded compound **15** as a single diastereomer. Multiplicity of the newly formed oxymethine proton signal in the ^1^H-NMR spectrum of **15** was ddd (*J* = 10.3, 5.2, 3.4 Hz), indicating that the reduction proceeded selectively from the β-side of the molecule. Removal of all protecting groups of **15** yielded a benzoic acid **16**, and subsequent treatment with SOCl~2~ in MeOH followed by Wittig olefination provided an 8-hydroxy analog **18**. Conversely, removal of the hydroxyl group of **15** was achieved with the *Barton--McCombie* deoxygenation reaction \[[@B11-marinedrugs-13-07074]\] to yield **20**, which was converted in the same manner as analog **18** to yield an 8-desmethyl analog **23**.

![Synthesis of 8-methyl group-modified analogs. Reagents and conditions: (**a**) NaBH~4~, CeCl~3~·7H~2~O, MeOH, 94%; (**b**) 80% TFA, THF, 50 °C, **16**: 97%, **21**: 93%; (**c**) SOCl~2~, MeOH, 50 °C, **17**: 98%, **22**: 87%; (**d**) Ph~3~PCH~3~Br, KHMDS, THF, **18**: 39%, **23**: 95%; (**e**) NaH, CS~2~, THF, rt, then MeI, 50 °C, 94%; (**f**) *n*Bu~3~SnH, AIBN, toluene, 80 °C, 86%.](marinedrugs-13-07074-g008){#marinedrugs-13-07074-f008}

2.3. Biological Evaluation of Synthetic Analogs {#sec2dot3-marinedrugs-13-07074}
-----------------------------------------------

Following the synthesis of the desired analogs, growth inhibitory activities of the analogs against DU145 cells were evaluated under normoxic and hypoxic conditions. As briefly summarized in [Figure 4](#marinedrugs-13-07074-f004){ref-type="fig"}, the majority of the analogs lost the hypoxia-selective growth inhibitory activity of the parent natural product. Thus, methyl ether analog **7**, 17-*O*-propargyl analog **8**, and 18-*O*-propargyl analog **9** did not possess hypoxia-selectivity. These results suggested that the 17-hydroxyl group might be necessary for hypoxia selectivity and the 18-hydroxyl group was partially concerned with growth inhibitory activity. In contrast, octyl ester analog **5**, 17-*O*-nonyl ether analog **10**, and 18-*O*-nonyl analog **11** showed only weak hypoxia-selective growth inhibitory activity. Because these analogs were highly lipophilic, this significant change in their physical properties might affect their biological activity. Furthermore, all the *exo*-olefin-modified analogs (**12a**,**12b**,**13**) and 8-hydroxyl analog (**18**) lost hypoxic/normoxic selectivity, while 8-desmethyl analog **23** showed moderate hypoxia-selective growth inhibitory activity. These results indicated that the *exo*-olefin might be an essential moiety for hypoxia-selective growth inhibitory activity and the 8-methyl group also affected growth inhibition. Taken together, not only the *para*-hydroxybenzoyl moiety but also the decalin part, including 4-*exo*-olefin and 8-methyl groups, were essential for the hypoxia-selective growth inhibitory activity of **1** and **2**. Of the synthesized analogs, only the propargyl amide analog **6** showed excellent hypoxia-selective growth inhibitory activity. In particular, potent and hypoxia-selective growth inhibitory activity was observed at 30 µM relative to the parent compound ([Figure 5](#marinedrugs-13-07074-f005){ref-type="fig"}).

![Growth inhibitory activity of dictyoceratin analogs against DU145 cells. \* *p \<* 0.05.](marinedrugs-13-07074-g004){#marinedrugs-13-07074-f004}

![Growth inhibitory activity of dictyoceratin-C (**1**) and propargyl amide analog (**6**) against DU145 cells. \* *p \<* 0.05.](marinedrugs-13-07074-g005){#marinedrugs-13-07074-f005}

3. Experimental Section {#sec3-marinedrugs-13-07074}
=======================

3.1. General {#sec3dot1-marinedrugs-13-07074}
------------

The following instruments were used to obtain physical data: a JASCO P-2200 digital polarimeter (L = 50 mm) for specific rotations; a JEOL ECS-300 (^1^H-NMR: 300 MHz, ^13^C-NMR: 75 MHz), ECA-500 (^1^H-NMR: 500 MHz, ^13^C-NMR: 125 MHz) and a Varian NMR system (^1^H-NMR: 600 MHz, ^13^C-NMR: 150 MHz) spectrometer for ^1^H and ^13^C NMR data using tetramethylsilane or residual solvent peak as internal standards; a JASCO FT/IR-5300 infrared spectrometer for IR spectra; a Waters Q-Tof Ultima API mass spectrometer for ESI-TOF MS; HPLC was performed using a Hitachi L-6000 pump equipped with Hitachi L-4000H UV detector. Silica gel (Kanto, 40--100 μm) and pre-coated thin layer chromatography (TLC) plates (Merck, 60F~254~) were used for column chromatography and TLC. Spots on TLC plates were detected by spraying acidic *p*-anisaldehyde solution (*p*-anisaldehyde: 25 mL, *c*-H~2~SO~4~: 25 mL, AcOH: 5 mL, EtOH: 425 mL) or phosphomolybdic acid solution (phosphomolybdic acid: 25 g, EtOH: 500 mL) with subsequent heating. Unless otherwise noted, all the reaction was performed under N~2~ atmosphere. After workup, the organic layer was dried over Na~2~SO~4~. ^1^H and ^13^C NMR spectra of compounds **4**--**23** are available in the [supplementary information](#marinedrugs-13-07074-s001){ref-type="supplementary-material"}.

3.2. In Vivo Anti-Tumor Effect of Dictyoceratin-C (**1**) and -A (**2**) {#sec3dot2-marinedrugs-13-07074}
------------------------------------------------------------------------

All procedures of animal experiment were approved as No. DOUYAKU24-8 by the Committee on Animal Experimentation of Osaka University. Murine sarcoma S180 cells (1 × 10^6^ cells/body), suspended in the RPMI1640 without FBS and kanamycin, were subcutaneously implanted into the right ventral flank of female ddY mice of 6 weeks old. After one week from implantation, dictyoceratin-C (**1**) or -A (**2**) was orally administered on every other day for two week (total seven times) as a suspension in 1% sodium carboxymethyl cellulose (CMC-Na). Then, tumor was isolated and weighed to calculate the ratio of inhibition. The control group and the groups treated with **1** or **2** consisted of six mice each in this study.

3.3. Design and Synthesis of Structure-Modified Analogues {#sec3dot3-marinedrugs-13-07074}
---------------------------------------------------------

### 3.3.1. 4-Hydroxy-3-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoic acid (**4**) {#sec3dot3dot1-marinedrugs-13-07074}

Under an Ar atmosphere, KHMDS (5.9 mL, of a 0.5 M solution in toluene, 3.0 mmol) was added to a solution of Ph~3~PCH~3~Br (1.05 g, 3.0 mmol) in anhydrous THF (1.9 mL), and the whole mixture was stirred for 1 h at rt. The above solution (7.2 mL, about 2.7 mmol) was added dropwise to a solution of **3** (93.5 mg, 0.27 mmol) in anhydrous THF (0.9 mL) at 0 °C, and the whole mixture was stirred for 20 h at rt. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 3:2) to give **4** (87.3 mg, 94%) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +33 (*c* = 1.22, MeOH). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.85--7.83 (2H, m), 6.76 (1H, d, *J* = 8.6 Hz), 4.42 (1H, s), 4.37 (1H, s), 2.70 (1H, d, *J* = 14.4 Hz), 2.63 (1H, d, *J* = 14.4 Hz), 2.34 (1H, td, *J* = 13.6, 5.1 Hz), 2.12--2.06 (2H, m), 1.95--1.91 (1H, m), 1.64--1.56 (1H, m), 1.48 (1H, dt, *J* = 12.4, 3.1 Hz), 1.44--1.19 (5H, m), 1.07 (3H, s), 1.04 (3H, d, *J* = 6.7 Hz), 0.95 (1H, dd, *J* = 12.2, 1.8 Hz), 0.89 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 171.9, 159.9, 159.4, 135.7, 130.1, 125.2, 121.2, 115.5, 102.9, 48.1, 42.1, 40.2, 37.1, 36.5, 36.3, 32.9, 27.9, 27.7, 23.3, 20.5, 17.62, 17.57. MS (ESI-TOF) *m*/*z*: 365 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 365.2093 calcd for C~22~H~30~O~3~Na; Found: 365.2083.

### 3.3.2. Octyl 4-hydroxy-3-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoate (**5**) {#sec3dot3dot2-marinedrugs-13-07074}

The components SOCl~2~ (6.0 µL, 0.083 mmol) and DMF (1 drop) were added to a solution of **4** (4.8 mg, 0.014 mmol) in anhydrous THF (0.2 mL), and the whole mixture was stirred for 1 h at rt. *n*-Octanol (6.0 µL, 0.083 mmol) was added to the mixture, and the whole mixture was stirred for 7 h at 50 °C. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (CHCl~3~/MeOH/H~2~O = 200:3:1, lower phase) to give **5** (0.8 mg, 13%) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +14 (*c* = 0.31, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.78 (1H, dd, *J* = 8.2, 1.9 Hz), 7.75 (1H, d, *J* = 1.9 Hz), 6.73 (1H, d, *J* = 8.2 Hz), 5.17 (1H, s), 4.41 (1H, s), 4.37 (1H, s), 4.31--4.20 (2H, m), 2.67 (1H, d, *J* = 14.3 Hz), 2.62 (1H, d, *J* = 14.3 Hz), 2.34 (1H, td, *J* = 13.7, 5.2 Hz), 2.08 (2H, t, *J* = 11.7 Hz), 1.94--1.91 (1H, m), 1.76--1.70 (2H, m), 1.60 (2H, qd, *J* = 13.2, 6.6 Hz), 1.47--1.41 (5H, m), 1.31--1.23 (10H, m), 1.07 (3H, s), 1.03 (3H, d, *J* = 6.9 Hz), 0.96 (1H, dd, *J* = 12.0, 1.7 Hz), 0.88 (3H, t, *J* = 6.9 Hz), 0.88 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 166.6, 159.9, 158.5, 134.8, 129.3, 124.8, 122.5, 115.3, 102.9, 64.8, 47.9, 42.0, 40.2, 37.0, 36.5, 36.2, 33.0, 31.8, 29.3, 29.2, 28.8, 27.9, 27.7, 26.1, 23.3, 22.7, 20.5, 17.63, 17.60, 14.1. IR (KBr) : 2926, 1672, 1599, 1279 cm^−1^. MS (ESI-TOF) *m*/*z*: 477 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 477.3345 calcd for C~30~H~46~O~3~Na; Found: 477.3348.

### 3.3.3. 4-Hydroxy-*N*-(prop-2-yn-1-yl)-3-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzamide (**6**) {#sec3dot3dot3-marinedrugs-13-07074}

Propargylamine (7.0 µL, 0.10 mmol), EDCI·HCl (18.0 mg, 0.094 mmol) and HOBt (14.2 mg, 0.11 mmol) were added to a solution of **4** (10.8 mg, 0.032 mmol) in anhydrous DMF (0.3 mL), and the whole mixture was stirred for 6 h at rt. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (CHCl~3~/MeOH/H~2~O = 30:3:1, lower phase) to give **6** (7.2 mg, 60%) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +22.0 (*c* = 0.58, MeOH). ^1^H-NMR (500 MHz, acetone-*d*~6~) δ: 8.89 (1H, d, *J* = 4.0 Hz), 7.79 (1H, brs), 7.71 (1H, d, *J* = 2.3 Hz), 7.61 (1H, dd, *J* = 8.6, 2.3 Hz), 6.86 (1H, d, *J* = 8.6 Hz), 4.37 (1H, s), 4.33 (1H, s), 4.20--4.09 (2H, m), 2.72 (1H, d, *J* = 14.3 Hz), 2.68 (1H, d, *J* = 14.3 Hz), 2.63 (1H, t, *J* = 2.6 Hz), 2.35 (1H, td, *J* = 13.7, 5.2 Hz), 2.22 (1H, d, *J* = 13.2 Hz), 2.08--2.04 (1H, m), 1.90--1.85 (1H, m), 1.62--1.54 (1H, m), 1.51--1.36 (4H, m), 1.21--1.15 (1H, m), 1.07 (3H, s), 1.05 (3H, d, *J* = 5.7 Hz), 1.01 (1H, dd, *J* = 11.7, 2.0 Hz), 0.89 (3H, s). ^13^C-NMR (125 MHz, acetone-*d*~6~) δ: 166.8, 160.7, 160.0, 133.6, 127.0, 126.0, 125.8, 115.4, 103.2, 81.8, 71.6, 48.9, 42.7, 40.9, 37.6, 37.5, 37.1, 33.7, 29.2, 28.8, 28.4, 23.7, 20.9, 18.1, 18.0. IR (KBr): 3299, 2921, 1630, 1588, 1490, 1268 cm^−1^. MS (ESI-TOF) *m*/*z*: 402 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 402.2409 calcd for C~25~H~33~NO~2~Na; Found: 402.2418.

### 3.3.4. Methyl 4-methoxy-3-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoate (**7**) {#sec3dot3dot4-marinedrugs-13-07074}

K~2~CO~3~ (7.5 mg, 0.054 mmol) and MeI (6.0 µL, 0.096 mmol) were added to a solution of **1** (6.8 mg, 0.018 mmol) in anhydrous DMF (0.2 mL), and the whole mixture was stirred for 12.5 h at rt. Sat. Na~2~S~2~O~3~ aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 8:1) to give **7** (7.6 mg, quantitative yield) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ +23 (*c* = 0.68, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.87 (1H, dd, *J* = 8.9, 1.7 Hz), 7.74 (1H, d, *J* = 1.7 Hz), 6.82 (1H, d, *J* = 8.9 Hz), 4.40 (1H, s), 4.35 (1H, s), 3.87 (3H, s), 3.81 (3H, s), 2.68 (1H, d, *J* = 14.3 Hz), 2.65 (1H, d, *J* = 14.3 Hz), 2.33 (1H, td, *J* = 13.5, 5.2 Hz), 2.11--2.08 (2H, m), 1.95--1.92 (1H, m), 1.58--1.53 (2H, m), 1.45 (1H, dt, *J* = 12.4, 3.3 Hz), 1.41--1.30 (3H, m), 1.25--1.15 (1H, m), 1.06 (3H, s), 1.01 (3H, d, *J* = 6.3 Hz), 0.88 (1H, d, *J* = 12.6 Hz), 0.86 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 167.2, 162.1, 160.1, 134.1, 129.4, 127.4, 121.5, 109.6, 102.7, 55.1, 51.8, 48.0, 42.1, 40.2, 36.7, 36.6, 36.3, 33.1, 27.9, 27.7, 23.2, 20.6, 17.6, 17.5. IR (KBr): 2927, 1719, 1437, 1298, 1269 cm^−1^. MS (ESI-TOF) *m*/*z*: 393 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 393.2406 calcd for C~24~H~34~O~3~Na; Found: 393.2414.

### 3.3.5. Methyl 3-hydroxy-4-(prop-2-yn-1-yloxy)-5-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoate (**8**); Methyl 4-hydroxy-3-(prop-2-yn-1-yloxy)-5-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoate (**9**) {#sec3dot3dot5-marinedrugs-13-07074}

K~2~CO~3~ (13.3 mg, 0.096 mmol) and propargyl bromide (9.0 µL, of a 80 wt% in toluene, 0.10 mmol) were added to a solution of **2** (30.6 mg, 0.082 mmol) in anhydrous DMF (1.65 mL), and the whole mixture was stirred for 3 h at 0 °C and for 13 h at rt. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 5:1) to give **8** (11.9 mg, 35%) as a colorless amorphous and **9** (4.3 mg, 13%) as a colorless amorphous.

**8**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +22 (*c* = 0.94, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.48 (1H, d, *J* = 2.0 Hz), 7.38 (1H, d, *J* = 2.0 Hz), 5.74 (1H, s), 4.59 (1H, dd, *J* = 15.5, 2.5 Hz), 4.53 (1H, dd, *J* = 15.5, 2.5 Hz), 4.40 (1H, s), 4.35 (1H, s), 3.87 (3H, s), 2.66 (1H, d, *J* = 13.7 Hz), 2.62 (1H, d, *J* = 13.7 Hz), 2.58 (1H, t, *J* = 2.5 Hz), 2.37--2.28 (1H, m), 2.10--2.07 (1H, m), 1.99 (1H, d, *J* = 13.2 Hz), 1.94--1.88 (1H, m), 1.57 (1H, qd, *J* = 13.0, 3.3 Hz), 1.45 (1H, dt, *J* = 12.4, 3.3 Hz), 1.42--1.33 (2H, m), 1.27--1.13 (3H, m), 1.05 (3H, s), 1.00 (3H, d, *J* = 6.3 Hz), 0.87 (3H, s), 0.84 (1H, dd, *J* = 12.0, 1.7 Hz). ^13^C-NMR (150 MHz, CDCl~3~) δ: 166.7, 159.8, 149.0, 148.8, 132.8, 126.2, 125.9, 115.2, 102.9, 78.2, 76.8, 61.0, 52.1, 47.8, 42.4, 40.1, 37.7, 36.4, 36.1, 32.9, 27.7, 27.5, 23.2, 20.6, 17.8, 17.6. IR (KBr): 3302, 2928, 1718, 1591, 1437, 1262 cm^−1^. MS (ESI-TOF) *m*/*z*: 433 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 433.2355 calcd for C~26~H~34~O~4~Na; Found: 433.2372.

**9**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +14 (*c* = 0.36, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.493 (1H, d, *J* = 2.0 Hz), 7.486 (1H, d, *J* = 2.0 Hz), 6.12 (1H, s), 4.78 (2H, d, *J* = 2.2 Hz), 4.41 (1H, s), 4.36 (1H, s), 3.87 (3H, s), 2.68 (2H, s), 2.58 (1H, t, *J* = 2.3 Hz), 2.34 (1H, td, *J* = 13.7, 5.2 Hz), 2.14--2.07 (2H, m), 1.92 (1H, m), 1.66--1.52 (1H, m), 1.48--1.36 (3H, m), 1.32--1.17 (3H, m), 1.06 (3H, s), 1.03 (3H, d, *J* = 6.9 Hz), 0.94 (1H, dd, *J* = 11.7, 2.0 Hz), 0.87 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 167.0, 160.2, 149.7, 143.9, 128.5, 125.0, 120.4, 111.1, 102.6, 77.6, 76.5, 57.3, 51.9, 48.0, 42.1, 40.2, 36.9, 36.6, 36.3, 33.0, 27.9, 27.7, 23.1, 20.6, 17.7, 17.6. IR (KBr): 3295, 2926, 1713, 1437, 1300 cm^−1^. MS (ESI-TOF) *m*/*z*: 433 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 433.2355 calcd for C~26~H~34~O~4~Na; Found: 433.2364.

### 3.3.6. Methyl 3-hydroxy-4-(nonyloxy)-5-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoate (**10**); Methyl 4-hydroxy-3-(nonyloxy)-5-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a-trimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoate (**11**) {#sec3dot3dot6-marinedrugs-13-07074}

K~2~CO~3~ (9.2 mg, 0.067 mmol) and *n*-nonyl bromide (8.0 µL, 0.042 mmol) were added to a solution of **2** (12.6 mg, 0.034 mmol) in anhydrous DMF (0.34 mL), and the whole mixture was stirred for 3 h at rt. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 30:1 to 5:1) to give **10** (3.6 mg, 21%) as a colorless amorphous and **11** (2.3 mg, 14%) as a colorless amorphous.

**10**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +15 (*c* = 0.20, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.43 (1H, d, *J* = 1.7 Hz), 7.36 (1H, d, *J* = 1.7 Hz), 6.16 (1H, s), 4.41 (1H, s), 4.36 (1H, s), 4.07 (2H, t, *J* = 6.6 Hz), 3.86 (3H, s), 2.69 (1H, d, *J* = 14.0 Hz), 2.66 (1H, d, *J* = 14.0 Hz), 2.34 (1H, td, *J* = 13.5, 5.2 Hz), 2.13--2.07 (2H, m), 1.94--1.90 (1H, m), 1.85--1.79 (2H, m), 1.62--1.52 (3H, m), 1.48--1.19 (16H, m), 1.06 (3H, s), 1.03 (3H, d, *J* = 6.3 Hz), 0.96 (1H, dd, *J* = 12.0, 1.7 Hz), 0.89 (3H, t, *J* = 6.9 Hz), 0.87 (3H, s). ^13^C-NMR (150 MHz, CDCl~3~) δ: 167.2, 160.3, 149.4, 145.3, 127.4, 124.2, 120.3, 109.9, 102.6, 69.2, 51.9, 48.0, 42.1, 40.2, 36.9, 36.6, 36.4, 33.1, 31.9, 29.5, 29.4, 29.2, 29.1, 27.9, 27.7, 26.0, 23.1, 22.7, 20.7, 17.7, 17.6, 14.1. IR (KBr): 2925, 1716, 1437, 1301 cm^−1^. MS (ESI-TOF) *m*/*z*: 521 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 521.3607 calcd for C~32~H~50~O~4~Na; Found: 521.3616.

**11**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +20 (*c* = 0.61, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.46 (1H, d, *J* = 2.0 Hz), 7.36 (1H, d, *J* = 2.0 Hz), 5.57 (1H, s), 4.40 (1H, s), 4.35 (1H, s), 3.87 (3H, s), 3.84--3.74 (2H, m), 2.66 (1H, d, *J* = 14.0 Hz), 2.58 (1H, d, *J* = 14.0 Hz), 2.31 (1H, td, *J* = 13.6, 5.5 Hz), 2.08 (1H, dd, *J* = 14.0, 3.2 Hz), 2.01 (1H, d, *J* = 12.6 Hz), 1.91--1.87 (1H, m), 1.83--1.77 (2H, m), 1.69--1.51 (3H, m), 1.47--1.11 (16H, m), 1.05 (3H, s), 0.99 (3H, d, *J* = 6.9 Hz), 0.89 (3H, t, *J* = 7.2 Hz), 0.87 (3H, s), 0.84 (1H, dd, *J* = 12.0, 1.7 Hz). ^13^C-NMR (150 MHz, CDCl~3~) δ: 166.8, 159.8, 149.9, 148.9, 132.2, 125.8, 125.5, 114.4, 102.9, 74.6, 52.0, 47.9, 42.3, 40.1, 37.3, 36.5, 36.1, 33.0, 31.8, 30.2, 29.5, 29.4, 29.2, 27.9, 27.6, 26.0, 23.1, 22.7, 20.6, 17.8, 17.5, 14.1. IR (KBr): 3394, 2926, 1722, 1437, 1335 cm^−1^. MS (ESI-TOF) *m*/*z*: 521 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 521.3607 calcd for C~32~H~50~O~4~Na; Found: 521.3630.

### 3.3.7. Methyl 4-hydroxy-3-(((1*S*,2*R*,4a*S*,5*S*,8a*S*)-1,2,4a,5-tetramethyldecahydronaphthalen-1-yl)methyl)benzoate (**12a**); Methyl 4-hydroxy-3-(((1*S*,2*R*,4a*S*,5*R*,8a*S*)-1,2,4a,5-tetramethyldecahydronaphthalen-1-yl)methyl)benzoate (**12b**) {#sec3dot3dot7-marinedrugs-13-07074}

An amount of 10% Pd-C (6.8 mg) was added to a solution of **1** (15.4 mg, 0.041 mmol) in anhydrous MeOH (2.0 mL), and the whole mixture was stirred for 16 h under H~2~ atmosphere (baloon). The mixture was filtered through a short pad of Celite. Removal of the solvent from the filtrate under reduced pressure gave a crude product, which was purified by reversed-phase HPLC (Cosmosil AR-II, 85% aq. CH~3~CN, flow rate: 3 mL/min, UV: 220 nm) to give **12a** (7.5 mg, 51%) and **12b** (7.0 mg, 47%) as a white amorphous solid.

**12a**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ −3.8 (*c* = 0.66, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.83 (1H, d, *J* = 2.2 Hz), 7.79 (1H, dd, *J* = 8.5, 2.2 Hz), 6.78 (1H, d, *J* = 8.5 Hz), 5.22 (1H, s), 3.88 (3H, s), 2.63 (2H, s), 1.91--1.83 (2H, m), 1.69--1.55 (3H, m), 1.48--1.31 (3H, m), 1.28--1.21 (2H, m), 1.17--1.11 (2H, m), 1.04 (3H, s), 0.99 (3H, d, *J* = 6.3 Hz), 0.88 (1H, dt, *J* = 13.0, 3.2 Hz), 0.82 (3H, s), 0.70 (3H, d, *J* = 6.9 Hz). ^13^C-NMR (150 MHz, CDCl~3~) δ: 167.2, 158.8, 135.0, 129.2, 125.1, 121.8, 115.3, 51.8, 42.2, 41.1, 38.8, 36.8, 36.51, 36.48, 36.4, 29.1, 27.6, 23.5, 22.1, 21.2, 17.7, 17.5, 14.6. IR (KBr): 3291, 2934, 1680, 1601, 1420, 1285 cm^−1^. MS (ESI-TOF) *m*/*z*: 381 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 381.2406 calcd for C~23~H~34~O~3~Na; Found: 381.2413.

**12b**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ −6.5 (*c* = 0.67, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.80 (1H, d, *J* = 2.0 Hz), 7.78 (1H, dd, *J* = 8.4, 2.0 Hz), 6.76 (1H, d, *J* = 8.4 Hz), 5.25 (1H, s), 3.88 (3H, s), 2.63 (2H, s), 1.93 (1H, d, *J* = 12.0 Hz), 1.84--1.80 (1H, m), 1.67--1.42 (5H, m), 1.40--1.13 (5H, m), 1.01 (3H, d, *J* = 6.3 Hz), 0.90 (1H, dd, *J* = 12.3, 2.6 Hz), 0.84 (3H, s), 0.80 (3H, s), 0.65 (3H, d, *J* = 6.9 Hz). ^13^C-NMR (125 MHz, CDCl~3~) δ: 167.1, 158.7, 135.1, 129.2, 125.0, 122.0, 115.3, 51.8, 48.9, 45.4, 41.6, 38.3, 37.3, 36.9, 36.1, 30.8, 27.5, 26.4, 23.1, 17.73, 17.68, 15.0, 13.2. IR (KBr): 2928, 1717, 1692, 1283 cm^−1^. MS (ESI-TOF) *m*/*z*: 381 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 381.2406 calcd for C~23~H~34~O~3~Na; Found: 381.2413.

### 3.3.8. Methyl 4-hydroxy-3-(((1*S*,2*R*,4a*R*,8a*R*)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl)methyl)benzoate (**13**) {#sec3dot3dot8-marinedrugs-13-07074}

**Compound 1** (7.6 mg, 0.020 mmol) and RhCl~3~·3H~2~O (2.6 mg, 0.010 mmol) were mixed and dried. EtOH (1.0 mL) was added to the mixture, and the whole mixture was stirred for 12 h under reflux. Removal of the solvent from the mixture under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 5:1) and reversed-phase HPLC (Cosmosil AR-II, 85% aq. CH~3~CN, flow rate: 3 mL/min, UV: 220 nm) to give **13** (4.0 mg, 61%) as a white amorphous solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ −27 (*c* = 0.39, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.80 (1H, d, *J* = 2.0 Hz), 7.77 (1H, dd, *J* = 8.6, 2.0 Hz), 6.74 (1H, d, *J* = 8.6 Hz), 5.27 (1H, s), 5.15 (1H, s), 3.87 (3H, s), 2.72 (1H, d, *J* = 14.6 Hz), 2.68 (1H, d, *J* = 14.6 Hz), 2.27--2.19 (1H, m), 2.13--2.08 (1H, m), 2.04 (1H, dd, *J* = 13.5, 6.6 Hz), 1.66--1.55 (2H, m), 1.50 (3H, d-like, *J* = 1.7 Hz), 1.38--1.25 (3H, m), 1.18 (1H, dd, *J* = 12.0, 1.1 Hz), 1.03 (3H, d, *J* = 6.3 Hz), 1.02 (3H, s), 0.93--0.88 (1H, m), 0.88 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 167.1, 158.7, 144.1, 135.2, 129.3, 125.0, 122.1, 120.6, 115.3, 51.8, 45.5, 41.7, 38.3, 37.2, 36.0, 35.7, 27.7, 26.0, 20.0, 19.9, 18.1, 17.7, 17.6. IR (KBr): 2944, 1688, 1603, 1433, 1285 cm^−1^. MS (ESI-TOF) *m*/*z*: 379 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 379.2249 calcd for C~23~H~32~O~3~Na; Found: 379.2252.

### 3.3.9. *tert*-Butyl 3-(((4a′*R*,5′*R*,6′*R*,8a′*R*)-6′-hydroxy-5′,8a′-dimethyloctahydro-2′*H*-spiro\[\[1,3\]dioxolane-2,1′-naphthalen\]-5′-yl)methyl)-4-(methoxymethoxy)benzoate (**15**) {#sec3dot3dot9-marinedrugs-13-07074}

CeCl~3~·7H~2~O (545 mg, 1.46 mmol) was added to a solution of **14** (285 mg, 0.58 mmol) \[[@B9-marinedrugs-13-07074]\] in MeOH (5.8 mL), and the whole mixture was stirred for 5 min. NaBH~4~ (110 mg, 2.9 mmol) was added to the mixture at 0 °C, and the whole mixture was stirred for 2.5 h at 0 °C. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 4:1) to give **15** (270 mg, 94%) as a white amorphous solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ −8 (*c* = 1.07, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.87 (1H, dd, *J* = 8.9, 2.0 Hz), 7.68 (1H, d, *J* = 2.0 Hz), 7.14 (1H, d, *J* = 8.9 Hz), 5.28 (2H, s), 3.86 (1H, q, *J* = 6.1 Hz), 3.79--3.76 (2H, m), 3.71 (1H, q, *J* = 6.5 Hz), 3.52 (3H, s), 3.37 (1H, d, *J* = 3.4 Hz), 3.00 (1H, ddd, *J* = 10.3, 5.2, 3.4 Hz), 2.82 (1H, d, *J* = 14.3 Hz), 2.59 (1H, d, *J* = 14.3 Hz), 1.93 (1H, d, *J* = 13.2 Hz), 1.76--1.61 (2H, m), 1.58 (9H, s), 1.57--1.45 (5H, m), 1.31--1.22 (2H, m), 1.10 (3H, s), 0.97 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 165.6, 158.9, 133.6, 129.4, 126.7, 125.5, 113.2, 113.0, 95.1, 80.7, 73.0, 65.0, 64.7, 56.8, 43.7, 43.1, 41.4, 35.8, 30.4, 28.3, 28.2, 25.0, 22.6, 21.3, 17.2, 16.6. MS (ESI-TOF) *m*/*z*: 513 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 513.2828 calcd for C~28~H~42~O~7~Na; Found: 513.2829.

### 3.3.10. 4-Hydroxy-3-(((1*R*,2*R*,4a*R*,8a*R*)-2-hydroxy-1,4a-dimethyl-5-oxodecahydronaphthalen-1-yl)methyl)benzoic acid (**16**) {#sec3dot3dot10-marinedrugs-13-07074}

An amount of 80% TFA (3.6 mL) was added to a solution of **15** (51.5 mg, 0.11 mmol) in THF (1.2 mL) at 0 °C, and the whole mixture was stirred for 3.5 h at 50 °C. Removal of the solvent from the mixture under reduced pressure gave a crude product, which was purified by SiO~2~ column (CHCl~3~/MeOH/H~2~O = 15:3:1, lower phase) to give **16** (36.6 mg, 97%) as a white amorphous solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ +14 (*c* = 1.02, MeOH). ^1^H-NMR (500 MHz, acetone-*d*~6~) δ: 7.77 (1H, dd, *J* = 8.6, 2.0 Hz), 7.69 (1H, d, *J* = 2.0 Hz), 6.88 (1H, d, *J* = 8.6 Hz), 3.06--3.03 (1H, m), 2.81 (1H, d, *J* = 14.3 Hz), 2.76 (1H, d, *J* = 14.3 Hz), 2.65 (1H, td, *J* = 14.0, 7.1 Hz), 2.27 (1H, dd, *J* = 14.0, 2.0 Hz), 2.18--2.13 (1H, m), 2.08--2.07 (1H, m), 1.96 (1H, qd, *J* = 13.0, 3.6 Hz), 1.76--1.59 (3H, m), 1.44 (1H, dt, *J* = 14.1, 3.3 Hz), 1.35--1.25 (2H, m), 1.20 (3H, s), 1.15 (1H, dd, *J* = 12.3, 2.0 Hz), 1.10 (3H, s). ^13^C-NMR (125 MHz, acetone-*d*~6~) δ: 213.7, 167.5, 162.0, 134.8, 130.7, 124.5, 122.6, 117.1, 73.9, 49.0, 47.2, 44.3, 37.7, 37.3, 32.0, 26.1, 26.0, 21.7, 19.6, 17.2. MS (ESI-TOF) *m*/*z*: 369 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 369.1678 calcd for C~20~H~26~O~5~Na; Found: 369.1680.

### 3.3.11. Methyl 4-hydroxy-3-(((1*R*,2*R*,4a*R*,8a*R*)-2-hydroxy-1,4a-dimethyl-5-oxodecahydronaphthalen-1-yl)methyl)benzoate (**17**) {#sec3dot3dot11-marinedrugs-13-07074}

SOCl~2~ (0.02 mL, 0.28 mmol) was added to a solution of **16** (23.6 mg, 0.068 mmol) in anhydrous MeOH (0.7 mL), and the whole mixture was stirred for 6.5 h at 45 °C. Removal of the solvent from the mixture under reduced pressure gave a crude product, which was purified by SiO~2~ column (CHCl~3~/MeOH/H~2~O = 60:3:1, lower phase) to give **17** (23.9 mg, 98%) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ +12 (*c* = 0.82, MeOH). ^1^H-NMR (500 MHz, acetone-*d*~6~) δ: 7.74 (1H, dd, *J* = 8.2, 1.9 Hz), 7.67 (1H, d, *J* = 1.9 Hz), 6.89 (1H, d, *J* = 8.2 Hz), 3.80 (3H, s), 3.04 (1H, dd, *J* = 10.3, 5.7 Hz), 2.88 (1H, br), 2.82 (1H, d, *J* = 14.9 Hz), 2.77 (1H, d, *J* = 14.9 Hz), 2.66 (1H, td, *J* = 14.0, 7.0 Hz), 2.27 (1H, dd, *J* = 14.0, 2.0 Hz), 2.22--2.17 (1H, m), 2.10--2.06 (1H, m), 2.03--1.97 (1H, m), 1.75--1.55 (3H, m), 1.44 (1H, dt, *J* = 14.3, 3.4 Hz), 1.33--1.23 (2H, m), 1.21 (3H, s), 1.16--1.13 (1H, dd, *J* = 12.3, 2.3 Hz), 1.11 (3H, s). ^13^C-NMR (125 MHz, acetone-*d*~6~) δ: 213.6, 167.0, 162.1, 134.5, 130.3, 124.6, 122.3, 117.1, 73.9, 51.9, 49.0, 47.2, 44.3, 37.7, 37.3, 32.0, 26.1, 26.0, 21.7, 19.6, 17.2. MS (ESI-TOF) *m*/*z*: 383 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 383.1834 calcd for C~21~H~28~O~5~Na; Found: 383.1847.

### 3.3.12. Methyl 4-hydroxy-3-(((1*R*,2*R*,4a*R*,8a*S*)-2-hydroxy-1,4a-dimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)benzoate (**18**) {#sec3dot3dot12-marinedrugs-13-07074}

Under an Ar atmosphere, KHMDS (0.9 mL, of a 0.5 M solution in toluene, 0.45 mmol) was added to a solution of Ph~3~PCH~3~Br (165 mg, 0.46 mmol) in anhydrous THF (0.22 mL), and the whole mixture was stirred for 1 h at rt. The above solution was added dropwise to a solution of **17** (10.9 mg, 0.030 mmol) in anhydrous THF (0.1 mL) at 0 °C, and the whole mixture was stirred for 1 h at rt. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 3:1) to give **18** (5.6 mg, 39%) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ −32 (*c* = 0.55, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.81 (1H, dd, *J* = 8.5, 1.9 Hz), 7.63 (1H, d, *J* = 1.9 Hz), 6.89 (1H, d, *J* = 8.5 Hz), 4.45 (1H, s), 4.37 (1H, s), 3.85 (3H, s), 3.12 (1H, dd, *J* = 11.7, 4.3 Hz), 2.71 (2H, s), 2.31 (1H, td, *J* = 13.7, 5.7 Hz), 2.16--2.09 (2H, m), 2.04--2.00 (1H, m), 1.78 (1H, qd, *J* = 12.6, 3.2 Hz), 1.71--1.56 (4H, m), 1.48--1.40 (1H, m), 1.36 (1H, td, *J* = 13.3, 3.8 Hz), 1.11 (3H, s), 1.03 (3H, s), 1.00 (1H, dd, *J* = 12.6, 2.3 Hz). ^13^C-NMR (150 MHz, CDCl~3~) δ: 167.1, 160.9, 158.5, 133.9, 129.8, 123.2, 121.7, 116.6, 103.2, 74.7, 51.8, 46.2, 43.1, 39.5, 36.6, 34.8, 32.7, 27.4, 26.9, 22.1, 21.2, 16.3. IR (KBr): 3210, 2938, 1721, 1435, 1289 cm^−1^. MS (ESI-TOF) *m*/*z*: 381 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 381.2042 calcd for C~22~H~30~O~4~Na; Found: 381.2032.

### 3.3.13. *tert*-Butyl 3-(((4a′*R*,5′*R*,6′*R*,8a′*R*)-5′,8a′-dimethyl-6′-(((methylthio)carbonothioyl)oxy)octahydro-2′*H*-spiro\[\[1,3\]dioxolane-2,1′-naphthalen\]-5′-yl)methyl)-4-(methoxymethoxy)benzoate (**19**) {#sec3dot3dot13-marinedrugs-13-07074}

Under an Ar atmosphere, NaH (91.0 mg, 60% suspension in oil, 2.3 mmol) was added to a solution of **15** (136 mg, 0.28 mmol) in anhydrous THF (2.8 mL) at 0 °C, and the whole mixture was stirred for 30 min at rt. CS~2~ (0.17 mL, 2.8 mmol) was added dropwise to the mixture, and the whole mixture was stirred for 50 min at rt. MeI (0.21 mL, 3.4 mmol) was added to the mixture, and the whole mixture was stirred for 5 h at 50 °C. Sat. Na~2~S~2~O~3~ aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 5:1) to give **19** (152 mg, 94%) as a white amorphous solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ −18 (*c* = 1.17, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.79 (1H, dd, *J* = 8.6, 2.3 Hz), 7.68 (1H, d, *J* = 2.3 Hz), 7.02 (1H, d, *J* = 8.6 Hz), 5.18 (2H, dd, *J* = 8.0, 6.9 Hz), 5.13 (1H, dd, *J* = 11.2, 4.3 Hz), 3.92--3.88 (3H, m), 3.79--3.77 (1H, m), 3.43 (3H, s), 2.96 (1H, d, *J* = 14.0 Hz), 2.64 (1H, d, *J* = 14.0 Hz), 2.28--2.24 (1H, m), 2.19 (3H, s), 1.88 (1H, d, *J* = 12.6 Hz), 1.80 (1H, dd, *J* = 12.0, 2.3 Hz), 1.77--1.61 (3H, m), 1.58 (9H, s), 1.54--1.44 (4H, m), 1.39--1.35 (1H, m), 1.17 (3H, s), 1.15 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 213.4, 165.8, 158.8, 133.6, 129.3, 127.1, 124.6, 113.0, 112.9, 93.9, 88.7, 80.4, 65.2, 64.9, 56.2, 45.7, 43.2, 38.9, 30.4, 28.2 (3C), 27.7, 22.8, 21.6, 21.0, 17.8, 17.0, 16.9. MS (ESI-TOF) *m*/*z*: 603 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 603.2426 calcd for C~30~H~44~O~7~S~2~Na; Found: 603.2449.

### 3.3.14. *tert*-Butyl 3-(((4a′*R*,5′*R*,8a′*R*)-5′,8a′-dimethyloctahydro-2′*H*-spiro\[\[1,3\]dioxolane-2,1′-naphthalen\]-5′-yl)methyl)-4-(methoxymethoxy)benzoate (**20**) {#sec3dot3dot14-marinedrugs-13-07074}

Under an Ar atmosphere, *n*Bu~3~SnH (0.21 mL, 0.80 mmol) and AIBN (34.5 mg, 0.21 mmol) were added to a solution of **19** (138 mg, 0.24 mmol) in anhydrous toluene (3.4 mL), and the whole mixture was stirred for 3 h at 80 °C. H~2~O was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 8:1) to give **20** (96.6 mg, 86%) as a white amorphous solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ +21 (*c* = 1.26, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.79 (1H, dd, *J* = 8.6, 2.3 Hz), 7.70 (1H, d, *J* = 2.3 Hz), 7.07 (1H, d, *J* = 8.6 Hz), 5.21 (1H, d, *J* = 6.9 Hz), 5.18 (1H, d, *J* = 6.9 Hz), 3.94--3.89 (3H, m), 3.83--3.79 (1H, m), 3.46 (3H, s), 2.88 (1H, d, *J* = 13.0 Hz), 2.40 (1H, d, *J* = 13.0 Hz), 1.81 (1H, d, *J* = 13.2 Hz), 1.75--1.64 (2H, m), 1.61--1.58 (1H, m), 1.57 (9H, s), 1.52--1.50 (1H, m), 1.44--1.21 (8H, m), 1.10 (3H, s), 0.85 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 165.9, 159.5, 134.1, 128.9, 127.9, 124.3, 113.5, 112.7, 94.2, 80.4, 65.2, 64.8, 56.2, 47.6, 43.8, 42.3, 37.9, 37.6, 30.6, 30.2, 28.2 (3C), 23.0, 20.9, 19.3, 17.8, 17.1. MS (ESI-TOF) *m*/*z*: 497 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 497.2879 calcd for C~28~H~42~O~6~Na; Found: 497.2897.

### 3.3.15. 3-(((1*R*,4a*R*,8a*R*)-1,4a-Dimethyl-5-oxodecahydronaphthalen-1-yl)methyl)-4-hydroxybenzoic acid (**21**) {#sec3dot3dot15-marinedrugs-13-07074}

An amount of 80% TFA (4.0 mL) was added to a solution of **20** (74.9 mg, 0.16 mmol) in THF (2.0 mL), and the whole mixture was stirred for 2.5 h at 50 °C. Removal of the solvent from the mixture under reduced pressure gave a crude product, which was purified by SiO~2~ column (CHCl~3~/MeOH/H~2~O = 30:3:1, lower phase) to give **21** (50.0 mg, 93%) as a white amorphous solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ +46 (*c* = 1.13, MeOH). ^1^H-NMR (500 MHz, acetone-*d*~6~) δ: 7.75 (1H, dd, *J* = 8.6, 2.3 Hz), 7.74 (1H, d, *J* = 2.3 Hz), 6.92 (1H, d, *J* = 8.6 Hz), 2.77 (1H, d, *J* = 13.2 Hz), 2.70--2.60 (1H, m), 2.61 (1H, d, *J* = 13.2 Hz), 2.16--2.07 (2H, m), 1.83 (1H, qd, *J* = 12.9, 3.7 Hz), 1.69--1.40 (4H, m), 1.37--1.26 (5H, m), 1.20 (3H, s), 1.05 (3H, s). ^13^C-NMR (125 MHz, acetone-*d*~6~) δ: 214.3, 161.1, 135.6, 130.3, 125.8, 122.0, 115.7, 78.1, 51.1, 49.7, 42.5, 39.6, 37.88, 37.86, 33.8, 26.6, 21.8, 21.4, 19.4, 18.2. MS (ESI-TOF) *m*/*z*: 353 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 353.1729 calcd for C~20~H~26~O~4~Na; Found: 353.1730.

### 3.3.16. Methyl 3-(((1*R*,4a*R*,8a*R*)-1,4a-dimethyl-5-oxodecahydronaphthalen-1-yl)methyl)-4-hydroxybenzoate (**22**) {#sec3dot3dot16-marinedrugs-13-07074}

SOCl~2~ (0.03 mL, 0.413 mmol) was added to a solution of **21** (30.3 mg, 0.092 mmol) in anhydrous MeOH (0.92 mL), and the whole mixture was stirred for 15 h at 50 °C. Removal of the solvent from the mixture under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 3:1) to give **22** (27.5 mg, 87%) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{25}$ +46 (*c* = 0.73, MeOH). ^1^H-NMR (500 MHz, acetone-*d*~6~) δ: 9.10 (1H, br s), 7.72 (1H, dd, *J* = 8.6, 1.7 Hz), 7.70 (1H, d, *J* = 1.7 Hz), 6.91 (1H, d, *J* = 8.6 Hz), 3.81 (3H, s), 2.77 (1H, d, *J* = 13.2 Hz), 2.66 (1H, td, *J* = 13.7, 6.9 Hz), 2.60 (1H, d, *J* = 13.2 Hz), 2.16--2.08 (3H, m), 1.83 (1H, qd, *J* = 13.2, 3.7 Hz), 1.68--1.25 (7H, m), 1.20 (3H, s), 1.11 (1H, t, *J* = 7.2 Hz), 1.05 (3H, s). ^13^C-NMR (125 MHz, acetone-*d*~6~) δ: 214.2, 167.1, 161.1, 135.2, 130.0, 125.9, 121.8, 115.8, 51.8, 51.1, 49.7, 42.4, 39.6, 37.89, 37.86, 33.8, 26.6, 21.8, 21.4, 19.4, 18.2. MS (ESI-TOF) *m*/*z*: 367 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 367.1885 calcd for C~21~H~28~O~4~Na; Found: 367.1875.

### 3.3.17. Methyl 3-(((1*R*,4a*R*,8a*R*)-1,4a-dimethyl-5-methylenedecahydronaphthalen-1-yl)methyl)-4-hydroxybenzoate (**23**) {#sec3dot3dot17-marinedrugs-13-07074}

Under an Ar atmosphere, KHMDS (0.57 mL, of a 0.5 M solution in toluene, 0.29 mmol) was added to Ph~3~PCH~3~Br (114 mg, 0.32 mmol), and the whole mixture was stirred for 1 h at rt. The above solution was added dropwise to a solution of **22** (14.5 mg, 0.042 mmol) in anhydrous THF (0.21 mL) at 0 °C, and the whole mixture was stirred for 3.5 h at rt. Sat. NH~4~Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO~2~ column (*n*-hexane/AcOEt = 4:1) to give **23** (13.7 mg, 95%) as a white solid.

$\left\lbrack \mathsf{\alpha} \right\rbrack_{\text{D}}^{26}$ +60 (*c* = 0.89, CHCl~3~). ^1^H-NMR (500 MHz, CDCl~3~) δ: 7.78 (1H, dd, *J* = 8.3, 2.3 Hz), 7.73 (1H, d, *J* = 2.3 Hz), 6.78 (1H, d, *J* = 8.3 Hz), 5.28 (1H, br s), 4.47 (1H, s), 4.46 (1H, s), 3.87 (3H, s), 2.68 (1H, d, *J* = 13.5 Hz), 2.44 (1H, d, *J* = 13.5 Hz), 2.36 (1H, td, *J* = 13.7, 5.2 Hz), 2.15--2.11 (1H, m), 1.97--1.92 (2H, m), 1.62--1.46 (4H, m), 1.44--1.23 (4H, m), 1.11 (3H, s), 1.09 (1H, d, *J* = 12.0 Hz), 0.95 (3H, s). ^13^C-NMR (125 MHz, CDCl~3~) δ: 167.0, 160.2, 158.4, 134.9, 129.3, 124.9, 122.1, 115.2, 102.5, 51.9, 42.5, 40.2, 38.7, 38.1, 37.0, 33.0, 29.7, 28.4, 22.3, 20.8, 20.3, 18.4. IR (KBr): 2928, 1688, 1603, 1429, 1283 cm^−1^. MS (ESI-TOF) *m*/*z*: 365 \[M + Na\]^+^. HRMS (ESI-TOF) *m*/*z*: 365.2093 calcd for C~22~H~30~O~3~Na; Found: 365.2089.

3.4. Biological Evaluation of Analogues {#sec3dot4-marinedrugs-13-07074}
---------------------------------------

### 3.4.1. Cell Cultures {#sec3dot4dot1-marinedrugs-13-07074}

Human prostate cancer cell line DU145 was cultured in RPMI 1640 supplemented with heat-inactivated 10% fetal bovine serum (FBS) and kanamycin (50 μg/mL) in a humidified atmosphere of 5% CO~2~ at 37 °C.

### 3.4.2. Assay for Anti-Proliferative Activity under Hypoxic Condition {#sec3dot4dot2-marinedrugs-13-07074}

The DU145 cells in the culture medium were plated into each well of 96-well plates (1 × 10^4^ cells/well/200 μL) in a humidified atmosphere of 5% CO~2~ at 37 °C (normoxic condition). After 4 h, the plates were incubated for 12 h in the hypoxic condition (94% nitrogen, 5% CO~2~, and 1% O~2~) inducing hypoxia-related genes such as HIF-1α. Then, testing compounds were added, and the plates were incubated for additional 24 h in the hypoxic condition. The cell proliferation was detected by MTT method as previously described \[[@B8-marinedrugs-13-07074]\]. The growth inhibition rate was calculated as percentage of parallel negative controls. The anti-proliferative activities of the testing compounds under normoxic condition were also evaluated by the MTT method.

4. Conclusions {#sec4-marinedrugs-13-07074}
==============

In summary, we demonstrated the potential of dictyoceratin-C (**1**) and A (**2**) as anticancer drug leads by evaluating their *in vivo* antitumor activity. In addition, we investigated the SAR of **1** and **2** by using our synthetic methodology and concluded that the characteristic moieties of **1** were important for hypoxia-selective growth inhibition. This evidence conflicts with a previous study, which showed that the unnatural enantiomers of **1** and **2** also exhibited similar hypoxia-selective growth inhibitory activity. In order to clarify this contradiction, we focused on determining the target molecules of **1** and **2**. Substitution of the methyl ester of **1** with the more physiologically stable propargyl amide was found to be effective. Moreover, the propargyl group could be a useful tag for further functionalization through click chemistry, leading to the synthesis of probe molecules for target identification of **1** and **2**. These studies are now underway.
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